Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
SUTRO BIOPHARMA, INC.
| Metric | SUTRO BIOPHARMA, INC. STROOther |
|---|---|
| Quality Score | 49 / 100 |
| Revenue (latest) | $102M |
| Net income (latest) | −$191M |
| Operating margin | −154.5% |
| Net margin | −186.5% |
| Return on equity | 144.3% |
| Return on assets | −109.9% |
| Return on capital (ROCE) | −160.5% |
| Debt / equity | — |
| Revenue growth (YoY) | 65.2% |
| Altman Z″ (distress) | -22.06 |
| Accruals / assets | −8.0% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.